FDA Grants Priority Review to BeOne’s HER2+ GEA Combo Therapy
Event summary
- The FDA granted Priority Review to BeOne’s sBLA for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy for first-line HER2+ GEA.
- The regimen demonstrated a median overall survival of 26.4 months, a significant improvement over the control arm's 19.2 months.
- BeOne plans to use the FDA’s Project Orbis pathway to accelerate global approvals.
- The Phase 3 HERIZON-GEA-01 trial randomized 914 patients across 30+ countries.
The big picture
BeOne’s Priority Review designation marks a pivotal shift in the treatment of HER2+ gastroesophageal adenocarcinoma, a disease with stagnant survival rates for over a decade. The FDA’s Breakthrough Therapy Designation and Project Orbis participation underscore the global significance of these results, potentially reshaping the oncology market for HER2-targeted therapies.
What we're watching
- Regulatory Momentum
- The pace at which the FDA and international regulators will approve this combination therapy for broader use.
- Commercialization Strategy
- How BeOne plans to scale manufacturing and distribution to meet potential global demand.
- Competitive Landscape
- Whether this approval will pressure competitors to accelerate their own HER2-targeted therapies.
Related topics